Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.

In this study, researchers found that disrupting EGFR signaling in mice led to increased inflammation and hair follicle damage but that inhibiting the JAK-STAT1 pathway could restore hair growth and skin function.

This study investigated the effects of pathological α-synuclein on sebaceous gland cells in Parkinson's disease, finding that α-synuclein exposure altered cellular differentiation and lipid production, suggesting a potential link between α-synuclein and lipid dysregulation in the skin of PD patients.

In this study on fine-wool sheep, researchers found that overexpressing the TGFBR1 gene decreased proliferation of dermal papilla cells by influencing multiple signaling pathways, suggesting TGFBR1 as a negative regulator in hair follicle development.

In this review, the authors report that tacrolimus ointment shows promise for expanding its use to a variety of skin conditions, beyond its current approval for atopic dermatitis, by analyzing clinical experiences of its application for rosacea, seborrheic dermatitis, psoriasis, and other dermatoses.

In a study conducted on mice, researchers observed that exposure to ionizing radiation led to significant metabolic imbalances, including dyslipidemia and disruptions in amino acid metabolism, with activated protein C providing partial protection by normalizing certain plasma metabolites and lipids.

This report describes the case of identical twin males, where one applied topical 5% minoxidil for over a year on the beard and mustache area and the other did not, highlighting the anecdotal use of minoxidil for facial hair enhancement.

This study highlights the role of immune dysregulation, microRNA modulation, and SIRT1 pathways in alopecia areata, suggesting antisense oligonucleotides targeting miR-485-3p as a promising therapeutic strategy for promoting hair regrowth and reducing inflammation in murine models.

This study discovered that exosomes from adipose-derived mesenchymal stem cells can mitigate damage in dermal papilla cells by modulating the TGF-β1/SMAD2 signaling pathway through miRNAs miR-574-3p and miR-125a-5p, revealing potential therapeutic targets for androgenetic alopecia.

In this study, researchers found that ligand homodimerization controls the receptor binding specificity of the FGF9 subfamily, preventing off-target activation of FGFR "b" isoforms.

This study suggests that targeting adenosine receptors could be an effective strategy for reducing inflammation in inflammatory skin disorders, with promising results observed in animal models.

This review concludes that oral dutasteride has the highest evidence level for stabilizing frontal fibrosing alopecia and should be used as a first-line treatment until more randomized controlled trials are conducted.

This phase II study found that a 0.05% topical dutasteride solution was more effective than oral finasteride (1 mg/day) in increasing hair count and width in males with androgenetic alopecia over 24 weeks, without causing irritation.

This review focuses on the pharmacological properties, indications, contraindications, and safety profile of bicalutamide, a non-steroidal androgen receptor antagonist, in dermatological research, particularly its off-label use for improving female pattern hair loss as measured by Sinclair grading.

In this study, researchers found that TCDD exposure accelerated differentiation and altered gene expression in human epidermal cells, indicating the epidermal barrier as a target of TCDD-activated AHR.

This review examines the life cycle, biomarkers, and functions of hair follicle stem cells, emphasizing their role in hair loss therapy and other skin and hair disorders, but reports no new clinical results.

This study suggests that 20 vital medicinal herbs may exert therapeutic effects on alopecia by regulating specific target genes and proteins, offering insights into their novel mechanisms distinct from conventional drugs.

This study found that inhibiting the Mitochondrial Pyruvate Carrier in human scalp hair follicles caused metabolic stress that halted cell proliferation and disrupted key signaling pathways, with these effects partially reversed by an integrated stress response inhibitor.

In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.

This article reviews current literature and suggests that managing gout with early urate-lowering therapy, within a 'treat-to-target' strategy, can help prevent systemic complications and address the rising prevalence of hyperuricemia-related diseases.

This review discusses recent studies on the hepatotoxic effects of anabolic androgenic steroids and selective androgen receptor modulators, including liver damage, tumors, and related conditions, and reports no new primary research results.

This review discusses the integration of drug repurposing with personalized medicine through off-label prescribing and reports no new results, highlighting the potential for systematic exploration using omics technologies.

This review summarizes existing studies on sorafenib, noting its promising effects in some cancers, but also highlights its limitations and potential synergy when combined with other anticancer treatments.

In this study, researchers found that depleting mtDNA in mice caused skin wrinkles and hair loss but restoring mitochondrial function reversed these effects, highlighting mtDNA's significant role in skin and hair health.

This consensus concluded that oral isotretinoin is highly effective for treating acne and some off-label conditions, with common adverse events being manageable and rare serious risks not contraindicating use.

A new protein linked to Alzheimer's was discovered, and a hair loss treatment showed effectiveness but had some sexual side effects.

This review discusses the potential of therapeutic antibodies as an alternative treatment for androgenetic alopecia, highlighting the initial development stages and the need for further validation and optimization of targets like the prolactin receptor and Interleukin-6 receptor.

This chapter reviews current and emerging pharmacological treatments for alopecia, noting that the FDA's classification of alopecia as a cosmetic disease has limited drug development and led to off-label use of potentially dangerous compounds.

This review discusses methotrexate's use in dermatology and its mechanisms, pharmacokinetics, dosing, side effects, interactions, and emphasizes the need for further research into optimizing therapy and predicting adverse events.

The study reports that Fgf18 and Tgf-β2 signaling pathways in hair follicle stem cells have opposing effects on the timing of hair cycle transitions, influencing the shift from telogen to anagen phases.